

## CURRICULUM VITAE

Erika M.C.D'Agata MD MPH

**Business Address:** Rhode Island Hospital  
593 Eddy Street, Aldrich 720  
Providence, Rhode Island, 02903

**Electronic Mail Address:** edagata@lifespan.org

### EDUCATION

1986	Honors Bachelor of Science, University of Toronto, Toronto, Canada
1990	Medical Degree, University of Toronto, Toronto, Canada
1997	Master of Public Health with a concentration in Quantitative Methods, Harvard School of Public Health, Boston, Massachusetts

### POSTGRADUATE TRAINING

1990-1991	Internship in Internal Medicine, The Toronto Hospital, University of Toronto, Toronto, Canada
1991-1993	Residency in Internal Medicine, The Toronto Hospital, University of Toronto, Toronto, Canada
1993-1994	Clinical Fellow in Infectious Diseases, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, Massachusetts
1994-1997	Research Fellow in Infectious Diseases, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, Massachusetts
1994-1997	Postdoctoral Training Fellowship Program In Emerging Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

### POSTGRADUATE HONORS AND AWARDS

1982	Governor's General Medal, Canada
1982	Bursar's Scholarship in General Proficiency, Trinity College, University of Toronto, Canada
1984	Faculty Scholar Award, Trinity College, University of Toronto
1985	Dickinson-Cartwright 3TO Academic Scholarship, Trinity College, University of Toronto, Canada
1986	Edmund Murton Walker Academic Scholarship in Zoology, University of Toronto, Canada
1987	Health and Welfare Canada Grant, National Research and Development Program, Ottawa, Canada
1988	University of Toronto Medical Alumni Association Award
1988	International Health Exchange Program, Canadian Society for Tropical Medicine & International Health, Ottawa, Canada
1992	Housestaff Research Award, Mount Sinai Hospital, University of Toronto, Canada
1995	American Society of Microbiology Travel Grant
1996	Society of Healthcare and Epidemiology, Infectious Disease Fellow

	Scholarship
2001	Teaching Award in Infectious Diseases, Vanderbilt University Medical Center
2006	Society of Healthcare Epidemiology of America Investigator Award 2006
2006	Top Ten Publications in Infection Control and Hospital Epidemiology Journal of 2005. D'Agata EMC. Methodological issues of case-control studies: a review of established and newly recognized limitations. [editorial] Infect Control Hosp Epidemiol 2005;26:338-341
2007	Best Doctors List 2007, Boston Magazine
2008	New York Times, Health Section "Antibiotic questioned in care at life's end". Article on publication: D'Agata E, Mitchell S. Antimicrobial Utilization Patterns among Nursing Home Residents with Advanced Dementia. Arch Int Med 2008;168:357-62.
2019	Top Ten Publications in Infection Control and Hospital Epidemiology Journal of 2019. Araos R, D'Agata EMC. The microbiome and its role in infection control. Infect Control Hosp Epidemiol 2019;40:585-9.

### **PROFESSIONAL LICENSES AND BOARD CERTIFICATION**

1994	Diplomate, American Board of Internal Medicine
1996-present	Diplomate, American Board of Internal Medicine, Subspecialty: Infectious Disease
2001-2014	Massachusetts Registered Physician
2014-present	Rhode Island Registered Physician

### **ACADEMIC APPOINTMENTS**

1993-1994	Clinical Fellow, Harvard Medical School, Boston, MA
1994-1997	Research Fellow, New England Deaconess Hospital, Harvard Medical School, Boston, MA
1997-2001	Assistant Professor of Medicine, Department of Medicine, Vanderbilt University, Nashville, TN
2001-2002	Instructor in Medicine, Harvard Medical School, Boston, MA
2002-2008	Assistant Professor of Medicine, Harvard Medical School, Boston, MA
2009-2014	Associate Professor of Medicine, Harvard Medical School, Boston, MA
2014-2017	Associate Professor of Medicine, Brown University, Providence, Rhode Island
2017-present	Professor of Medicine, Brown University, Providence, Rhode Island
2017-present	Director of Research for Infectious Disease Fellows, Brown University, Providence, Rhode Island
2019-present	Section Director of Research, Division of Infectious Diseases, Brown University

### **HOSPITAL APPOINTMENTS**

1997-2001	Physician, Vanderbilt University Medical Center, Nashville, TN
1997-2001	Clinical Director, Molecular Epidemiology Section, Division of Infectious Diseases, Vanderbilt University, Nashville, TN
1997-2001	Consultant, Maury Regional Hospital, Columbia, TN
2006-2012	Physician, Hebrew Senior Life, Harvard Medical School, Boston, MA
2001-2014	Physician, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2014-present	Physician, Rhode Island Hospital and The Miriam Hospital, Brown University, Providence, Rhode Island

### **OTHER APPOINTMENTS**

2001-2006	Associate Hospital Epidemiologist, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2005-2011	Director, Hospital Epidemiology/Infection Control Unit, Beth Israel Deaconess-Needham Hospital, Needham, MA

### **HOSPITAL/UNIVERSITY COMMITTEES**

1999	Advisor, Resident Research Program, Vanderbilt University Medical Center, Nashville, TN
2000	Member, Committee for the Taskforce on Junior Faculty Career Development, Vanderbilt University, Nashville, TN
2000	Member, Review Committee, Vanderbilt University Medical Center 18 <sup>th</sup> Annual Research Forum, Nashville, TN
2000	Member, Clinical Microbiology Utilization Committee, Vanderbilt University Medical Center, Nashville, TN
2000-2001	Vice Chair, Infection Control Committee, Vanderbilt University Medical Center, Nashville, TN
2001-2005	Member, Antimicrobial Use Subcommittee, Pharmacy and Therapeutics Committee, Beth Israel Deaconess Medical Center
2002-2006	Member, Institutional Review Board, Beth Israel Deaconess Medical Center, East Campus
2004-2006	Harvard-Thorndike General Clinical Research Center Scientific Advisory Committee, Beth Israel Deaconess Medical Center, Boston, MA
2012-2014	BIDMC-Harvard T32 Translational Research in Aging Training Program Mentor and reviewer
2017-present	Faculty Academic Mentoring Committee, Division of Infectious Diseases, Brown University, Providence, Rhode Island
2019	Search Committee Member, Director of Geriatrics, Brown University Medical School
2019-present	Senior Faculty Mentoring Advisor Committee for the Centers of Biomedical Research Excellence Center for Antimicrobial Resistance and Therapeutic Discovery

### **GRANT REVIEW ACTIVITIES**

2009	NIGMS NIH Study Section: Modeling infectious disease agent systems Centers of Excellence March, 2009 Member
2013	NIGMS NIH Study Section: Modeling infectious disease agent systems Centers of Excellence December, 2013, Member
2014	NIGMS Study Section ZGM1 PPBC-5 (SP) Clinical Trials on Sepsis, March 2014, Member
2015	NIH Study Section ZRG1 HDM-W81 Community-level Health Promotion, November 2015, Member
2017	NIAID Study Section, Microbiology and Infectious Diseases Research Committee, May 2017, Member
2019	NIH Infectious Disease, Reproductive Health, and Asthma/Pulmonary Conditions ( <u>IRAP</u> ) study section, Feb. 2019, Member
2021-present	NIH/Agency of Healthcare Research and Quality, Healthcare Safety and Quality Improvement Research Study Section, Permanent Member

#### **OTHER NIH RELATED ACTIVITIES**

2016-2018	Data Safety Monitor for NIA R01 AG041780 Pathway from Functional Disability to Antimicrobial Resistance in Nursing Home Residents (PI Lona Mody MD)
2019-2020	Harvard Medical School T32 on Infectious Disease and Basic Microbiological Mechanisms.

#### **OTHER REVIEW ACTIVITIES**

2018	External Reviewer: 2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy
------	--

#### **NATIONAL COMMITTEES**

2016-2022	Member, Nephrologists Transforming Dialysis Safety Project, A collaborative between the Centers for Disease Control and Prevention and the American Society of Nephrology towards improving infection prevention in dialysis
-----------	--

#### **EDITORIAL ROLES**

Editorial Board	
2002- 2011	Editorial Board, Journal of Clinical Microbiology
2003- present	Editorial Board, Infection Control and Hospital Epidemiology
2004- 2020	Editorial Board, Clinical Infectious Diseases

Ad hoc Reviewer	
	Journal of Infectious Diseases, American Journal of Kidney Diseases, Antimicrobial Agents and Chemotherapeutics, JAMA

#### **MEMBERSHIP IN SOCIETIES**

1997-2002	American Society of Microbiology, member
1998-present	Infectious Disease Society of America, member
1999-present	Society for Healthcare Epidemiology of America, member

### **EDUCATIONAL INITIATIVES**

Antibiotic Prescribing Case-Based Learning Module. Centers for Disease Control and Prevention, American Society of Nephrology and, the Nephrologists Transforming Dialysis Safety. An on-line educational module targeting nephrologist healthcare workers towards improving antimicrobial prescribing patterns (<https://www.asn-online.org/ntds/>)

### **ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS**

1. **D'Agata E**, Venkataraman L, DeGirolami P, Samore M. The molecular epidemiology of acquisition of ceftazidime-resistant gram-negative strains in a non-outbreak setting. *J Clin Micro* 1997;35:2602-5.
2. **D'Agata E**, Venkataraman L, DeGirolami P, Weigel L, Samore M, Tenover F. The molecular epidemiology of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in a tertiary care hospital. *J Infect* 1998;36:279-85.
3. **D'Agata E**, Venkataraman L, DeGirolami P, Burke P, Eliopoulos G, Karchmer AW, Samore M. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors and rate of infection. *Crit Care Med* 1999;27:1090-5.
4. Ostrowski B, Venkataraman L, **D'Agata EMC**, Gold H, DeGirolami P, Samore M. Vancomycin-resistant enterococci in intensive care units: High frequency of stool carriage during non-outbreak periods. *Arch Int Med* 1999;159:1467-72.
5. Clough LA, **D'Agata E**, Raffanti S, Haas DW. Factors that predict incomplete virologic response to protease inhibitor-based antiretroviral therapy. *Clin Infect Dis* 1999;29:75-81.
6. **D'Agata EMC**, Venkataraman L, DeGirolami P, Samore M. The molecular epidemiology of ceftazidime-resistant gram-negative bacilli on inanimate surfaces and their role in cross-transmission during non-outbreak periods. *J Clin Micro* 1999;37:3065-7.
7. Green K, Schulman G, Haas DW, Schaffner W, **D'Agata EMC**. Vancomycin prescribing practices in hospitalized chronic hemodialysis patients. *Amer J Kid Dis* 2000;35:64-8.
8. **D'Agata EMC**, Mount DB, Thayer V, Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. *Amer J Kid Dis* 2000;35:1083-8.
9. **D'Agata EMC**, Thayer V, Schaffner W. An outbreak of *Acinetobacter baumannii*: the importance of cross-transmission. *Infect Control Hosp Epidemiol* 2000;21:588-92.
10. Luther JM, Lakey DL, Larson RS, Kallianpur AR, **D'Agata E**, Cousar JB, and Haas DW. Utility of bone marrow biopsy for rapid diagnosis of febrile illnesses in patients with AIDS. *South Med J* 2000;93:692-7.
11. **D'Agata EMC**, Green K, Schulman G, Li H, Tang YW, Schaffner W. Vancomycin-resistant enterococci among chronic hemodialysis patients. *Clin Infect Dis*. 2001;32:23-9.
12. **D'Agata EMC**, Stewart A, Lefkowitz LB. Nosocomial transmission of *Mycobacterium tuberculosis* from an extrapulmonary site. *Infect Control Hosp Epidemiol* 2001;22:10-3.
13. **D'Agata EMC**, Li H, Gouldin C, Tang YW. Clinical and molecular characterization of vancomycin-resistant *E.faecium* during endemicity. *Clin Infect Dis* 2001;33:511-6.

14. **D'Agata EMC**, Jirgis J, Gouldin C, Tang YW. Community dissemination of vancomycin-resistant *Enterococcus faecium* in the United States. *Am J Infect Control* 2001; 29:316-20.
15. **D'Agata EMC**, Gerrits MM, Tang YW, Samore M, Kusters JG. Comparison of pulsed-field gel electrophoresis and amplified-fragment length polymorphism for epidemiological investigations of common nosocomial pathogens. *Infect Control Hosp Epidemiol* 2001; 22:550-4.
16. **D'Agata EMC**, Gautam S, Green WK, Tang YW. High false negative rate of the rectal swab culture method in detecting gastrointestinal colonization with vancomycin-resistant enterococci. *Clin Infect Dis* 2002; 34:167-72.
17. Tang YW, Haas D, **D'Agata EMC**. Rapidly increasing prevalence of antimicrobial resistance among *S. pneumoniae* isolates in Tennessee: A ten-year clinical and molecular study. *J Clin Microbiol* 2002;40:395-9.
18. **D'Agata EMC**, Horn MA, Webb G. The impact of persistent gastrointestinal colonization on the transmission dynamics of vancomycin-resistant enterococci. *J Infect Dis* 2002;185:766-73.
19. Tacconelli E, **D'Agata EMC**, Karchmer AW. Epidemiological comparisons of true methicillin-resistant and methicillin-susceptible coagulase-negative staphylococcal bacteremia at hospital admission *Clin Infect Dis* 2003;37:644-9.
20. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foremann MG, **D'Agata EMC**. Mupirocin prophylaxis to prevent *Staphylococcus aureus* infections in dialysis patients: A Meta-Analysis *Clin Infect Dis* 2003; 37:1629-1638.
21. Tacconelli E, Venkataram L, DeGirolami T, **D'Agata EMC**. Methicillin-resistant *Staphylococcus aureus* bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains *J Antimicrobial Chemotherap* 2004;53:474-9.
22. Talbot TR, **D'Agata EMC**, Brinsko V, Lee B, Speroff T, Schaffner W. Perioperative blood transfusions is predictive of post-sternotomy surgical site infection : marker for morbidity or true immunosuppression. *Clin Infect Dis* 2004; 38:1378-82.
23. **D'Agata EMC** Rapidly rising prevalence of nosocomial multidrug-resistant gram-negative bacilli: a 9-year surveillance study. *Infect Control Hosp Epidemiol* 2004; 25; 842-6.
24. Tacconelli E, Yokoe D, **D'Agata EMC**. Preventing the influx of vancomycin-resistant enterococci into healthcare institutions, by use of a simple validated prediction rule. *Clin Infect Dis* 2004;39:964-70.
25. Pop-Vicas A, **D'Agata EMC**. The Rising Influx of Multi-Drug Resistant Gram-Negative Bacteria into a Tertiary Care Hospital. *Clin Infect Dis* 2005;40:1792-8.
26. **D'Agata EMC**, Webb G. Horn M. A mathematical model quantifying the impact of antibiotic exposure and other interventions on the endemic prevalence of vancomycin-resistant enterococci *J Infect Dis* 2005;192:2004-11.
27. Webb, GF, **D'Agata EMC**, Magal P, Ruan S. A Model of Antibiotic Resistant Bacterial Epidemics in Hospitals. *Proc Natl Acad Sci U S A*. 2005; 102:13343-8.
28. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, **D'Agata EMC**, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV-1 infection. *Clin Infect Dis* 2006;42:1024-31
29. **D'Agata EMC**, Cataldo MA, Cauda R, Tacconelli E. The importance of addressing multidrug resistance and not assuming single-drug resistance in case-control studies. *Infect Control Hosp Epidemiol* 2006 27:670-4.
30. **D'Agata EMC**, Magal P, Ruan S, Webb G. Asymptotic behavior behind nosocomial epidemic models with antibiotic resistance. *Diff Integral Equations* 2006;19:573-600.

31. Tacconelli E, Pop-Vicas A, **D'Agata EMC**. Increased mortality among elderly patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *J Hosp Infect* 2006;64;251-6.
32. **D'Agata EMC**, Magal P, Olivier D, Ruan S, Webb G. Modeling Antibiotic Resistance In Hospitals: The Impact of Minimizing Duration of Treatment. *J Theor Biol* 2007;249;487-99
33. **D'Agata EMC**, Horn MA, Webb G Quantifying the impact of bacterial fitness and repeated antimicrobial exposure on the emergence of multidrug-resistant gram-negative bacilli. *Math Mod Nat Phen* 2007;2;115-24.
34. Pop-Vicas A, Strom T, **D'Agata EMC**. Multidrug-resistant gram-negative bacilli among chronic hemodialysis patients. *Clin J Amer Soc Nephrol* 2008; 3;752-8.
35. **D'Agata E**, Mitchell S. Antimicrobial Utilization Patterns among Nursing Home Residents with Advanced Dementia. *Arch Int Med* 2008;168;357-62. PMID:18299489
36. Pop-Vicas A, Mitchell SL, Kandel R, Schreiber R, **D'Agata EMC**. Multidrug-resistant bacteria in a longterm care facility: prevalence and risk factors. *J Amer Geriatric Soc*. 2008; 56:1276-80. PMID:18557965
37. **D'Agata EMC**, Dupont-Rouzeryrol M, Magal P, Olivier D, Ruan S. The Impact of Different Antibiotic Regimens on the Emergence of Antimicrobial-Resistant Bacteria. *PLoS ONE* 2009;3(12): e4036 doi:10.1371/journal.pone.004035. PMID:19112501
38. O'Fallon E, Pop-Vicas A, **D'Agata EMC**. The emerging threat of multi-drug resistant gram -negative organisms in a long-term care facility. *J Gerontol A Biol Sci Med Sci*. 2009 Jan;64(1):138-41. PMID:19164271
39. **D'Agata EMC**, Webb GF, MA Horn, Moellering RC, Ruan S. Modeling the invasion of community-acquired methicillin-resistant *Staphylococcus aureus* into the hospital setting. *Clin Infect Dis* 2009;48;274-284. PMID:19137654
40. Pop-Vicas A, Tacconelli E, Gravenstein S, Lu B, **D'Agata EMC**. The Influx of multidrug-resistant gram-negative bacteria into the hospital setting and the role of the elderly. *Infect Control Hosp Epidemiol* 2009; 30:325-331. PMID:19220162
41. Johnson LE, **D'Agata EMC**, Paterson DL, Clarke L, Potoski BA, Peleg AY. *Pseudomonas aeruginosa* Bacteremia Over a 10-year Period: Multidrug Resistance and Outcomes in Transplant Recipients. *Transplant Infect Dis* 2009;11;227-34.
42. Peleg AY, Tilahun Y, Fiandaca MJ, **D'Agata EMC**, Venkataraman L, Moellering RC, Eliopoulos GM. Rapid detection of *Acinetobacter* spp. and *Pseudomonas aeruginosa* using peptide nucleic fluorescence *in situ* hybridization. *J Clin Microbiol* 2009; 47;830-2. PMID:19116347
43. O'Fallon E, Schreiber R, Kandel R, **D'Agata EMC**. Multidrug- Resistant Gram-Negative Bacteria within a Long-Term Care Facility: assessment of residents, health care workers and inanimate surfaces. *Infect Control Hosp Epidemiol*. 2009;30;1172-79. PMID:19835474
44. Pressley P, **D'Agata EMC**, Webb GF. The effect of co-colonization with community-acquired and hospital-acquired methicillin-resistant *Staphylococcus aureus* strains on competitive exclusion. *J Theoretical Biol* 2010;264;645-56. PMID:20347850
45. Webb GF, Horn MA, **D'Agata EMC**, Moellering RC, Ruan S. Competition of hospital-acquired and community-acquired methicillin-resistant *Staphylococcus aureus* in hospitals. *J Biol Dynamics* 2010;4;115-129 PMID:19587839
46. **D'Agata EMC**, Webb GF, Pressely J. Rapid emergence of co-colonization with community-acquired and hospital-acquired methicillin-resistant *Staphylococcus aureus* strains in the hospital setting. *Math Mod Nat Phen* 2010;5;76-83. PMID:20740067
47. O'Fallon E, Kandell R, Schreiber R, **D'Agata EMC**. Acquisition of Multidrug-Resistant Gram-Negative Bacteria: incidence and risk factors within a long-term care population. *Infect Control Hosp Epidemiol* 2010;31;1148-53. PMID:20923286

48. Snyder GM, O'Fallon E, **D'Agata EMC**. Co-Colonization with Multiple Different Species of Multidrug-Resistant Gram-Negative Bacteria. *Am J Infect Control* 2011;39:506-10. PMID:21492962
49. Snyder GM, **D'Agata EMC** Diagnostic accuracy of surveillance cultures to detect gastrointestinal colonization with multidrug-resistant gram-negative bacteria. *J Hosp Infect* 2012;40:474-6. PMID:21925768.
50. Grima DT, Webb GF, **D'Agata EMC**. Mathematical Model of the Impact of a Non-Antibiotic Treatment for *Clostridium difficile* on the Endemic Prevalence of Vancomycin-Resistant Enterococci in a Hospital Setting. *Comput Math Methods Med.* 2012:605861. PMID:22291852
51. **D'Agata EMC**, Horn MA, Ruan S, Webb GF, Wares J. A comprehensive transmission model of multidrug-resistant organisms in the hospital setting. *PLOS One* 2012; 7(2):e30170. PMID: 2233430
52. Doi Y, Adams-Haduch JM, Peleg AY, **D'Agata EMC**. The role of horizontal gene transfer in the dissemination of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates in an endemic setting. *Diagn Microbiol Infect Dis* 2012;74:34-8. PMID:22722012
53. Denkinger CM, Grant A, Denkinger M, Gautam S, **D'Agata EMC**. Increased Multi-drug Resistance among the Elderly on Admission to the Hospital - a 12-year Surveillance Study. *Arch Gerontol Geriatric* 2013;56:227-30. PMID:22682422.
54. **D'Agata EMC**, Loeb MB, Mitchell SL. Challenges assessing nursing home residents with advanced dementia for suspected urinary tract infections. *J Amer Soc Geriatr* 2013;61:62-6. PMID: 23311553.
55. Mitchell SL, Shaffer ML, Kiely DK, Givens JL, **D'Agata E**. The study of pathogen resistance and antimicrobial use in dementia: Study design and methodology. *Arch Gerontol Geriatr.* 2013; 56;16-22. PMID:18557965
56. Snyder GM, Patel PR, Kallen AJ, Strom JA, Tucker JK, **D'Agata EMC**. Antimicrobial use in out-patient dialysis units. *Infect Control Hosp Epidemiol* 2013;34:349-57. PMID:23466906
57. Mitchell SL, Shaffer ML, Loeb MB, Givens JL, Habtemariam D, Kiely DK, **D'Agata E**. Infections Management and Multidrug-resistant Organisms in Nursing Home Residents with Advanced Dementia. *JAMA Int Med* 2014;174:1660-7. PMID:25133863
58. **D'Agata EMC**, Habtemariam D, Mitchell SL. Multidrug-resistant gram-negative bacteria: intra- and inter- facility dissemination among residents with advanced dementia. *Infect Control Hosp Epidemiol* 2015;36:935. PMID:25920002
59. Givens JL, Spinellal S, Ankuda CK, **D'Agata E**, Shaffer ML, Habtemariam D, Mitchell SL. Healthcare proxy awareness of suspected infections in nursing home residents with advanced dementia. *J Am Geriat Soc* 2015;63:1084-90. PMID:26031905
60. Dufour AB, Shaffer ML, **D'Agata EM**, Habtemariam D, Mitchell SL. Survival after suspected urinary tract infections in advanced dementia. *J Am Geriat Soc* 2015;63:2472-7. PMID:26613981
61. Snyder G, Patel PR, Kallen AJ, Strom JA, Tucker JK, **D'Agata EMC**. Factors associated with the receipt of antimicrobials among chronic hemodialysis patients. *Am J Infect Control* 2016;44:1269-74.
62. Wares JR, Lawson B, Shemin D, **D'Agata EMC**. Evaluating infection prevention strategies in out-patient dialysis units using agent-based modeling. *PLOS One* 2016 19;11(5):e0153820. PMID:27195984
63. Araos, R, Tai AK, Snyder GM, Blaser MJ, **D'Agata EMC**. The protective role of *Lactobacillus* spp. Against Colonization with Multidrug-Resistant Organisms. *Clin Infect Dis* 2016;63:937-43. PMID:27358350



64. Shaffer M, **D'Agata E**, Habtemariam D, Mitchell SL. Examining the relationship between multidrug-resistant organism acquisition and exposure to antimicrobials in the long-term care population. *Ann Epidemiol* 2016;26:810-15 PMID:27751631
65. Snyder GM, McCoy C, **D'Agata EM**. Quantifying Antimicrobial Exposure: Hazards in Populations With End-Stage Renal Disease. *Infect Control Hosp Epidemiol*. 2016 Dec 5:1-4.
66. Araos R, Montgomery V, Ugalde JA, Snyder GM, **D'Agata EMC**. Microbial disruption indices to detect colonization with multidrug-resistant organisms. *Infect Control Hosp Epidemiol*. 2017;38:1312-8.
67. **D'Agata EMC**, Tran D, Bautista J, Shemin D, Grima D. The Clinical and Economic Benefits of Implementing Antimicrobial Stewardship Programs in Out-Patient Hemodialysis Units. *Clin J Am Soc Nephrol* 2018;13:1389-97.
68. Araos R, Andreatos N, Ugalde J, Mitchell S; Mylonakis E, **D'Agata EMC**. The fecal microbiome among nursing home residents with advanced dementia and *Clostridium difficile*. *Dig Dis Sci* 2018;63:1525-31.
69. **D'Agata EMC**, Lindberg C, Lindberg C, Shemin D, Rosen S. The positive effects of an antimicrobial stewardship program targeting out-patient hemodialysis facilities. *Infect Control Hosp Epi* 2018;39(12):1400-1405.
70. **D'Agata EMC**, Varu A, Geffert SF, Araos R, Mitchell S. Situ A, Cameron C. Acquisition of multidrug-resistant organisms in the absence of antimicrobial exposure. *Clin Infect Dis* 2018;67:1437-40.
71. **D'Agata EMC**, Geffert SF, McTavish R, Wilson F, Cameron C. Acquisition of multidrug-resistant organisms in the absence of antimicrobial exposure: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2019;40:1129-134.
72. Lindberg CM, Lindberg CC, **D'Agata EMC**, Esposito B, Downham G Advancing Antimicrobial Stewardship in Outpatient Dialysis Centers Using the Positive Deviance Process. *Nephrol Nurs J*. 2019 Sep-Oct;46(5):511-518
73. Qadeer F, Shemin D, Gillani FS, **D'Agata EMC**. The rise in gram-negative bacteria causing blood stream infections among maintenance hemodialysis patients. *Kidney Med* 2019;1:144-6.
74. Tharmalingam N, Ribeiro NQ, da Silva DL, Naik MT, Cruz LI, Kim W, Shen S, Dos Santos JD, Ezikovich K, **D'Agata EM**, Mylonakis E, Fuchs BB. Auranofin is an effective agent against clinical isolates of *Staphylococcus aureus*. *Future Med Chem*. 2019 11;1417-1425.
75. Loizeau AJ, **D'Agata EMC** , ML Shaffer, LC Hanson, RA Anderson, Tsai, T, Habtemariam DA, Bergman EH, Carroll RP, Cohen SM, Scott EM, Stevens E, Whyman JD. The Trial to Reduce Antimicrobial Use in Nursing Home Residents with Alzheimer's Disease and other Dementias: Protocol of a Hybrid Efficacy-Effectiveness Cluster Randomized Clinical Trial. *Trials* 2019;20:594-608.
76. Araos R, Battaglia T, Ugalde JA, Rojas-Herrera M, Blaser MJ, **D'Agata EMC**. Fecal microbiome characteristics and the resistome associated with acquisition of multidrug-resistant organisms among elderly subjects. *Front Microbiol* 2019 Sep 27;10:2260. doi: 10.3389/fmicb.2019.02260.
77. Shaffer M, **D'Agata EMC**, Habtemariam D, Mitchell S. Covariate-constrained randomization for cluster randomized trials in the long-term care setting: Application to the TRAIN-AD trial. *Contemporary Clinical Trials Communications*. 2020; 18, 2020 Mar 17;18:100558. doi: 10.1016/j.conctc.2020.100558.

78. Rowan-Nash AD, Araos R, **D'Agata EMC**, Belenky P. Antimicrobial Resistance Gene Prevalence in a Population of Patients With Advanced Dementia Is Related to Specific Pathobionts. *iScience* 2020;23:100905. doi: 10.1016/j.isci.2020.100905. Epub 2020 Feb 1.
79. Apata IW, Kabbani S, Neu AM, Kear TK, **D'Agata EMC**, Levenson DJ, Kliger A, Hicks LA, Patel PR, and the ASN and CDC Antibiotic Stewardship White Paper Writing Group. Opportunities to Improve Antibiotic Stewardship in Outpatient Hemodialysis Facilities. *Amer J Kid Dis* 2020;77:757-68.
80. Shehadeh F, Kalligeros M, Byrd K, Shemin D, Mylonakis E, Martin P, **D'Agata EMC**. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. *Sci Rep* 2020;10(1):14332. doi: 10.1038/s41598-020-71205-5.
81. Hendricksen M, Habtmariam D, **D'Agata EMC**, Mitchell SL. Factors associated with antimicrobial use in nursing home residents with advanced dementia. *J Am Med Dir Assoc. J Am Med Dir Assoc.* 2021 Jan;22(1):178-181.
82. **E.M.C D'Agata**, I.W. Apata, S. Booth, J.M. Boyce, K. Deaver, N. Gualandi, A. Neu, D. Nguyen, S. Novosad, P.M. Palevsky, D. Rodgers and the Nephrologist Transforming Dialysis Safety Committee. Suggestions for the prevention of *Clostridioides difficile* spread within outpatient hemodialysis facilities. *Kid Int* 2021;99:1045-53.
83. EA Argueta, MA Alsamman, SF Moss, **EMC D'Agata** Impact of antimicrobial resistance rates on eradication of *Helicobacter pylori* in a United States population. *Gastroenterology* 2021;160:2181–2183.
84. P.Radhakrishnan, M.Vishwanath, D.Shemin, JFG Monteiro, **EMC D'Agata**. *Clostridioides difficile* infection among patients requiring maintenance hemodialysis. *Kid Med* 2021;3:467-70.
85. Susan L.Mitchell, **Erika M.C.D'Agata**, Laura C. Hanson, Daniel A. Habtemariam, Erin M. E. Scott, Erin Stevens, Jeremy D Whyman, Timothy Tsai, Ruth A. Anderson, Michele L. Shaffer. The Trial to Reduce Antimicrobial use In Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD): A Cluster Randomized Clinical Trial to Improve Infection Management in Advanced Dementia *JAMA Int Med* 2021;81:1174-82.
86. Chetboun M, Raverdy V, Labreuche J. *et al*. BMI and pneumonia outcomes in critically ill COVID-19 patients: an international multicenter study. *Obesity* 2021 (*accepted*)
87. Hendricksen M, Loizeau AJ, Habtemariam DA, Anderson RA, Hanson LC, **D'Agata EMC**, Mitchell SL. Provider adherence to training components from the Trial to Reduce Antimicrobial use In Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD) intervention. *Contemp Clin Trials Commun.* 2022 Mar 25;27:100913. doi: 10.1016/j.conctc.2022.100913. PMID: 35369403; PMCID: PMC8965910.
88. Elfanagely Y, Tanzer JR, Shobayo A, Mohamed MFH, Ho JC, Shemin D, Pavlech L, **D'Agata EMC**. Prevalence and trends of *Clostridioides difficile* infection among persons requiring maintenance hemodialysis: A Systematic Review and Meta-Analysis. *Infect Control Hosp Epidemiol* 2022;23:1-8.
89. Erick A. Argueta \*, Jonathan J.C. Ho, Yousef Elfanagely, **Erika D'Agata**, Steven F.Moss, Clinical Implication of Drug Resistance for H. pylori Management *Antibiotics* 2022; 11(12):1684.
90. Araos R, Smith RM, Styczynski A, Sanchez F, Acevedo J, Maureira L, Paredes C, González M, Rivas L, Spencer M, Peters A, Khan A, Sepulveda D, Huidobro A, Ferreccio C, Park B, Undurraga E, **D'Agata EMC**, Jara A, Munita J. High burden of intestinal colonization with antimicrobial resistant bacteria in Chile: An Antibiotic
- 91.

## **BOOK CHAPTERS AND REVIEW ARTICLES**

1. **D'Agata E**, Mauer J. Hepatopulmonary syndrome. American College of Chest Physicians - Pulmonary Perspectives, [review] 1992; 9(3):5-7.
2. **D'Agata E**, Eliopoulos G. Infections in the diabetic patient. Clin Updates Infect Dis 1997;3:1-4.
3. Golper TA, Schulman G, **D'Agata EMC**. Indications for vancomycin in dialysis patients. Seminars Dialysis [editorial] 2000;13:389-392.
4. **D'Agata EMC**. Hospital-acquired infections among chronic hemodialysis patients. [review] Inf Med 2001;18:305-11.
5. **D'Agata EMC**. Antimicrobial-resistant gram-positive bacteria in the chronic hemodialysis population. [review] Clin Infect Dis 2002;35:1212-18
6. Pop-Vicas A, **D'Agata EMC**. Temporal trends of nosocomial multidrug-resistant gram-negative bacilli. [review] Contagion 2005;2:158-62.
7. **D'Agata EMC**. Methodological issues of case-control studies: a review of established and newly recognized limitations. [editorial] Infect Control Hosp Epidemiol 2005;26:338-341
8. Snyder G, **D'Agata EMC**. Novel Antimicrobial-Resistant Bacteria Among Patients Requiring Chronic Hemodialysis. [editorial] Current Opinion Nephrol Hypertension 2012;21:211-5. PMID:22240441
9. **D'Agata EMC**. Antimicrobial use and stewardship programs among dialysis centers. [editorial]. Sem Dial 2013;26:457-64. PMID:23600755
10. **D'Agata EMC**. *Pseudomonas* species, including *Pseudomonas aeruginosa*" In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (8<sup>th</sup> edition) 2015
11. Cunha CB, **D'Agata EMC**. Antimicrobial Stewardship in out-patient dialysis units. Curr Opin Nephrol Hypertens Nov 2016;25:551-5.
12. **D'Agata EMC**. Addressing the Problem of Multidrug-Resistant Organisms in Dialysis [perspectives]. Clin J Amer Soc Nephrol 2018;13:666-8.
13. **Araos R, D'Agata EMC**. *Pseudomonas* species, including *Pseudomonas aeruginosa*" In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (9<sup>th</sup> edition) 2018
14. Araos R, **D'Agata EMC**. The microbiome and its role in infection control. Infect Control Hosp Epidemiol 2019;40:585-9. (invited editorial).
15. **Araos R, D'Agata EMC**. *Pseudomonas* species, including *Pseudomonas aeruginosa*" In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (10<sup>th</sup> edition) 2023

## **INVITED PRESENTATIONS**

### **International**

- |      |  |
|------|--|
| 2004 | Visiting speaker, University of Rome, Medical School, Rome, Italy. "Transmission and dissemination of antimicrobial-resistant pathogens".  |
| 2004 | Lecturer, University of Rome, Division of Infectious Diseases, Rome, Italy. Post-doctoral course in infection control. Course #MD4112 "The epidemiology of vancomycin-resistant enterococci" |

- 2008 Invited Speaker, Population dynamics and Mathematical Biology Conference, Marseille, France. "Transmission dynamics of antimicrobial-resistant bacteria using mathematical modeling"
- 2010 Invited Speaker, Fields Institute, Toronto, Canada. Thematic program on the mathematics of drug resistance in infectious diseases.

### National

- 2003 Invited speaker, Infectious Disease Society of America 2003, San Diego, CA. Meet the professor session on Infection Control/Hospital Epidemiology.
- 2006 Invited speaker, Society for Healthcare Epidemiology 2006, Chicago, IL. Meet the professor session on Infection Control in the Hemodialysis Unit.
- 2007 Invited speaker, Society for Healthcare Epidemiology 2007, Washington, DC. Meet the professor session on Infection Control in the Hemodialysis Unit.
- 2009 Invited Speaker. 29<sup>th</sup> Annual Dialysis Conference, Houston, TX. Kinetics and modeling of disease transmission in dialysis units
- 2011 Invited speaker, Society for Healthcare Epidemiology 2011, Dallas, TX. Meet the professor session on Infection Prevention in Hemodialysis.
- 2011 Invited speaker, Society for Healthcare Epidemiology 2011, Dallas, TX. Multidrug-resistant gram-negative bacteria in long-term care facilities.
- 2011 Invited speaker, University of Miami, Coral Gables, Florida. Workshop "Antibiotic-resistant infections: mathematical modeling, transmission dynamics and control"
- 2012 Invited speaker, Society for Healthcare and Epidemiology of America, 2012, Jacksonville, Florida. , "Mathematical Modeling and Agent-Based Simulation in Infection Prevention"
- 2014 Invited speaker, Annual Dialysis Conference, Atlanta, GA. "Antimicrobial use in dialysis units"
- 2015 Invited speaker, American Society of Nephrology Annual Meeting, 2014, Philadelphia, PA. "Multidrug-resistant organisms in the dialysis unit: their impact and effective strategies for eradication"
- 2016 Invited speaker, National Kidney Spring Clinical Meeting, 2016, Boston, MA. "Antimicrobial Stewardship in Dialysis"
- 2016 Invited speaker, ID Week, 2016, New Orleans LA. "Strategy Implementation in Hemodialysis: Optimizing Antimicrobial Use"
- 2017 Invited speaker, End Stage Renal Disease Network 5 Healthcare-Associated Infections Learning and Action Network Webinar. "Antimicrobial Stewardship Programs in Dialysis"
- 2017 Invited speaker, Kidney Week, 2017, New Orleans LA. Antimicrobial stewardship programs in out-patient dialysis units.
- 2017 Invited speaker, Nephrologist Transforming Dialysis Safety (NTDS) Webinar "Antimicrobial Stewardship in Dialysis Units.
- 2017 Invited speaker, Centers for Disease Control and Prevention webinar "Antimicrobial stewardship programs in out-patient dialysis units"
- 2019 Invited speaker, The Centers for Medicare & Medicaid Services Quality Conference, "Antimicrobial Stewardship in Outpatient Dialysis Facilities"
- 2019 Invited speaker, Kidney Week 2019, Washington DC. "Clinical and Economic impact of antimicrobial stewardship programs in dialysis facilities"
- 2019 Invited speaker, Kidney Week 2019, Washington DC.

- 2021 “Multidrug-resistant organisms and *C.difficile* in dialysis facilities”  
Invited speaker, ID Week 2021, Antibiotic Prescribing, Antibiotic Resistance and Antimicrobial Stewardship Strategies in Dialysis Centers
- 2021 Invited speaker, “Preventing the spread of *C.difficile* in dialysis units”.  
Nephrologists Transforming Dialysis Safety Webinar
- 2022 Invited speaker, Annual Dialysis Conference. “Preventing *C.difficile* spread in outpatient HD”

**Regional**

- 2000 Vanderbilt University Medical Center, Infectious Disease Grand Rounds  
“Establishment of endemicity of vancomycin-resistant enterococci at a tertiary care institution”, lecturer, one hour.
- 2000 Vanderbilt University Medical Center. Nephrology Grand Rounds,  
“Vancomycin-resistant enterococci in the dialysis population”, lecturer, one hour.
- 2000 Vanderbilt University Medical Center, Medical Grand Rounds, “The epidemiology of vancomycin-resistant enterococci”, lecturer, one hour.
- 2002 Harvard School of Public Health, Interdisciplinary Program in the Epidemiology of Infectious Diseases Lecture Series. “Multidrug-resistant bacteria in the community”, lecturer, one hour.
- 2005 Harvard-wide Infectious Disease Conference. “Transmission dynamics of antimicrobial resistant pathogens using mathematical modeling”, lecturer, 30 minutes.
- 2006 Harvard-Thorndike General Clinical Research Center Crown Life Seminar Series in Research. “Modeling the spread of antimicrobial-resistance”
- 2006 Geriatrics Grand Rounds “Preventing the spread of antimicrobial-resistant bacteria”, Beth Israel Deaconess Medical Center, Boston, MA
- 2006 Invited speaker “Transmission dynamics of antimicrobial-resistant bacteria using mathematical modeling”, Infectious Diseases Grand Rounds, University of Massachusetts, Boston, MA
- 2007 Invited speaker, Veterans Administration Medical Center Medical Grand Rounds, Boston MA. “Multidrug-resistant gram-negative bacilli – an emerging threat
- 2008 Invited speaker “Multidrug-resistant gram-negative bacteria”, Infectious Diseases Grand Rounds, University of Massachusetts, Boston, MA
- 2009 Invited speaker, Veterans Administration Medical Center Medical Grand Rounds, Boston MA. “Transmission dynamics of multidrug-resistant gram-negative bacilli
- 2010 Invited speaker. “Infection Control Update”, Grand Rounds, BID-Needham campus, Boston, MA
- 2011 Invited speaker. “Multidrug-resistant gram-negative bacteria: the emerging threat” Grand Rounds, BID-Needham campus, Boston, MA
- 2013 Invited speaker. “The Evolution of Antimicrobial Resistance” Frontiers in Medicine, Beth Israel Deaconess Medical Center, Boston, MA
- 2014 Invited speaker. “Superspreaders of Antimicrobial-resistant Bacteria”, Boston University Medical Center, Boston, MA
- 2014 Invited speaker, “Antimicrobial use and resistance among chronic hemodialysis patients”, Renal Grand Rounds, Rhode Island Hospital, Providence, RI

2016	Invited speaker, "Multidrug-resistant organisms", Housestaff lectures, Rhode Island and Miriam Hospitals, Providence, Rhode Island
2021	Invited speaker, "Helicobacter pylori" Medical Grand Rounds, Rhode Island Hospital, Brown University, Providence, Rhode Island
2022	Invited speaker, "Preventing the spread of antimicrobial-resistant pathogens: current and novel approaches", Centers of Biomedical Research Excellence Center for Antimicrobial Resistance and Therapeutics, Brown University
2022	Discovery, Miriam Hospital, Brown University, Providence, RI Invited speaker: Antimicrobial resistance in the populations of hemodialysis". Rhode Island Hospital Renal Grand Rounds

## GRANTS

2023-2028	PI Agency of Healthcare Research and Quality 1R01HS029133 The INFECTADO Study: INFECTions Acquired by persons on maintenance hemoDialysis during hOspitalizations
2020-2025	PI Agency of Healthcare Research and Quality R01HS026895 Optimizing Antimicrobial Use in Maintenance Hemodialysis Units
2023-2024	PI NIH/National Institute of General Medical Sciences P20 GM121344 COBRE Center for Antimicrobial Resistance and Therapeutic Discovery
2022-2023	PI Universidad del Desarrollo, Santiago, Chile Platforms for studying transmission dynamics of emerging pathogens
2021	PI Brown Physicians Incorporated Academic Grant Transmission dynamics of <i>Helicobacter pylori</i>
2021	PI Brown Physicians Incorporated Translational Research Initiatives Multidisciplinary approach training in drug resistant pathogens T32 application
2016-2021	PI National Institute of Allergy and Infectious Diseases 1K24AI119158-01A1 Midcareer Investigator Award in Patient-Oriented Research
2019-2021	PI Brown Physicians Incorporated Academic Grant Antimicrobial resistance among <i>Helicobacter pylori</i> and treatment failure
2018-2019	Co-investigator Centers for Disease Control and Prevention BAA FY2018-OADS-01 Hospital and community burden of multidrug-resistant gram-negative bacteria in Chile
2016-2021	Collaborator National Institute of Aging

R01AG032982  
 Trial to reduce antimicrobial use in nursing home residents with Alzheimer's disease and other dementias (TRAIN-AD)

2016-2017 PI Centers for Disease Control and Prevention  
 Advanced and Innovative Solutions to Improve Public Health BAA 2016-N-17812  
 Rectal Microbiome Disruption Indices associated with acquisition of multidrug-resistant organisms among subjects exposed to antimicrobials

2013-2017 PI Agency of Healthcare Research and Quality  
 R18HS021666  
 Antimicrobial Use in Dialysis Units

2013-2015 co-PI National Institute of Aging  
 R21AG042325  
 A Pilot Study of an RCT to Improve Infection Management in LTCF

2009-2014 co-PI National Institute of Aging  
 R01AGG032982  
 Determinants, Decision Making and outcomes of antibiotic use in advanced dementia

2011-2012 PI Centers for Diseases Control and Prevention  
 10IPA1004108 Intergovernmental Personnel Act Assignment  
 Testing the Feasibility of Interventions Aimed At Improving Antibiotic Use In Out-Patient Hemodialysis Units

2010-2013 Collaborator National Science Foundation  
 DMS-1022728  
 Nonlinear dynamics in structures biological and epidemiological models

2010-11 PI AHRQ-Centers for Diseases Control and Prevention  
 10IPA1004108 Intergovernmental Personnel Act Assignment  
 Antibiotic Use In Out-Patient Hemodialysis Units

2007-11 Co-PI National Institute of General Medicine  
 R01 GM 083607-01  
 Collaborative Research: Mathematical modeling of the superspreaders of antibiotic-resistant bacteria

2006-08 PI National Institute of Diabetes and Digestive and Kidney  
 R21 DK077312- 01  
 Transmission dynamics of antimicrobial-resistant bacteria in dialysis units.

2004-05 PI Merck Pharmaceuticals  
 The epidemiology of multidrug-resistant gram-negative bacilli at hospital admission.

2004-06 Collaborator National Science Foundation no direct costs  
 NSF DMS-0412047

Spatial Heterogeneity, Nonlocal Interactions and Time Delay in  
Epidemiological and Biological Spread (Ruan)

- 2004-07 PI Merck Pharmaceuticals  
Outcomes of bacteremia secondary to multidrug-resistant gram-negative bacilli among elderly patients
- 2003-04 PI Genome Therapeutics  
Pharmacological intervention to prevent the dissemination of vancomycin-resistant enterococci
- 2003-04 PI Genome Therapeutics  
Mathematical modeling of the transmission dynamics of vancomycin-resistant enterococci.

**UNIVERSITY TEACHING ROLES**

- 1997 Introduction to Clinical Medicine, Harvard Medical School  
Second year students Preceptor 4 hours/week (8 weeks)
- 1998 Microbial Topics, Vanderbilt University School of Medicine  
First year medical students Tutor/Seminar leader 4 hours/week (24 weeks)
- 1998-2001 Pharmacology course lectures, Vanderbilt University School of Medicine  
Second year medical students Lecturer, two lectures/yr
- 2004-2005 Patient-Doctor II course, Harvard Medical School  
Second year students Educator 4hrs/week
- 2005 Mathematical modeling of infections and diseases. Modern Medical  
Microbe Hunters, Harvard Medical School  
Fourth year students Lecturer, one hour lecture
- 2002-2014 Mechanisms of Microbial Pathogenesis, HST course 040, Health, Service  
and Technology Medical Science, Harvard Medical School.  
Second year medical students Lecturer, one hour lecture/yr

**HOSPITAL TEACHING ROLES**

**Clinical Supervisory and Training Responsibilities**

- 1997-2001 Director, Clinical Investigator Track for Infectious Disease Fellows,  
Vanderbilt University, Nashville, TN. Supervising/mentoring clinical  
research track for Infectious Disease Fellows, 3-4 fellows per year,  
approximately 2 hours per week
- 2001-2006 Infectious Disease In-patient Consultative Service, Beth Israel Deaconess  
Medical Center  
Attending physician  
0-2 medical students, 1-3 medical residents, 5 infectious disease fellows  
4-12 weeks per year
- 2005-2011 Director, Hospital Epidemiology/Infection Control Unit, Beth Israel  
Deaconess-Needham Hospital, Needham, MA. Supervisory role of  
infection control nurse
- 2002-2014 Medicine Inpatient Service, Beth Israel Deaconess Medical Center  
Teaching Attending  
2-4 medical students, 2-4 medical residents, 4 weeks/year



2014-present Infectious Disease in-patient consultative service, Rhode Island and Miriam hospitals  
 Attending physician  
 0-2 medical students, 0-2 medical residents, 0-1 pharmacists, 1-2 infectious disease fellows  
 6 weeks per year

**Formal teaching of peers**

1998 Maury Regional Hospital, Columbia, TN. "Nosocomial infections", lecturer, one hour.  
 1999 Maury Regional Hospital, Columbia, TN. "Clinical implications of vancomycin-resistant enterococci", lecturer, one hour.  
 2003 "Transmission of antimicrobial-resistant pathogens: the impact of the GI tract as a reservoir". Controlling Nosocomial Infections symposium. Satellite symposium, Infectious Disease Society of America, San Diego, CA, lecturer, one hour.  
 2005 "Antimicrobial-resistant bacteria in longterm-care facilities" Hebrew Senior Life, Boston, MA, lecturer, one hour.  
 2005 "Preventing the transmission of antimicrobial-resistant bacteria in longterm-care facilities" Hebrew Senior Life, Boston, MA, lecturer, one hour  
 2007-2009 "Nosocomial Infections- An update" Saudi Aramco Medical Services Organization (SAMSO) Internal Medicine videoconference series, Partners Healthcare, Harvard Medical School, Boston, MA. Yearly lecture  
 2010 Antimicrobial-resistant bacteria in the longterm care setting. Division of Geriatrics, Beth Israel Deaconess Medical Center, Boston MA. Lecturer, one hour  
 2012 Mathematical Modeling in Infectious Diseases. Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston MA. Lecturer, one hour  
 2012 How to develop a systematic approach to manuscript writing. Division of Infectious Diseases. Beth Israel Deaconess Medical Center, Boston MA. Lecturer, one hour  
 2012 Principles of Mathematical Modeling. Clinical Investigator Training Program. BIDMC. Lecturer, one hour  
 2013 Antimicrobial resistance and antimicrobial use among chronic hemodialysis patients. Renal Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA,. Lecturer, one hour  
 2017 The microbiome and infection disease. Infectious Disease grand rounds, Miriam hospital, Providence, RI

**Formally Supervised Trainees, current position and accomplishments during years of mentoring**

1998-2000 William K.Green MD Assistant Professor of Medicine, Division of Infectious Diseases, University of South Alabama  
 Mentor: one first author publication in Clinical Infectious Diseases  
 2002-2004 Douglas Salvador MD MPH Associate Chief Medical Officer/Patient Safety Officer, Maine Medical Center  
 2003-2005 Sigall Kasutto MD Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

- Co-mentor. Dr.Kasutto was awarded the Charles King Award and was the first author on a publication in in the journal of Clinical Infectious Diseases
- 2004-2007 Aurora Pop-Vicas MD MPH Assistant Professor of Medicine, Brown University Medical School, Providence, Rhode Island  
Mentor: Dr. Pop-Vicas was the recipient of the BIDMC/Harvard Translational Research in Aging Training Program (T32) recipient. She was first author on four publications during her training period.
- 2005-2009 Erin O’Fallon MD MPH, Instructor of Medicine, Brigham and Womens Hospital, Harvard Medical School  
Mentor: Dr. O’Fallon was the recipient of the Hartford Foundation Grant and the Harvard Translational Research in Aging Training Program (T32). She has three first author publications in leading geriatric and infectious disease journals.
- 2007-2008 Laura Johnston MD Associate Director of Infection Control, Henry Ford Health System, Detroit, MI.  
Co-mentor: Her research years resulted in a first-author paper in Transplant Infectious Diseases
- 2008-2011 Claudia Denkinge MD MPH, Head of Tuberculosis and Hepatitis Branch, FIND Diagnostics, Geneva Switzerland  
External Advisor on her PhD Thesis at the London School of Tropical Medicine and Hygiene and a first author publication on the prevalence of multidrug-resistant gram-negative bacteria among hospitalized elderly patients.
- 2008-2014 Joanna Pressley/Wares PhD, Assistant Professor of Medicine, Dept. of Mathematics, University of Virginia  
Co-mentor. Dr.Pressley characterized the transmission dynamics of multidrug-resistant organisms in a variety of clinical settings.. She had 3 publications
- 2009-2016 Graham Snyder MD, Assistant Professor of Medicine, Harvard Medical School, Associate Director of Infection Control, BIDMC  
Mentor: Dr.Snyder is quantifying and characterizing antimicrobial use among out-patient hemodialysis units. Four publications and one review.
- 2012-present Rafael Araos MD, Assistant professor of Medicine, Universidad del Desarrollo School of Medicine  
Mentor: Dr.Araos is characterizing the microbiome and its relation to antimicrobial-resistant organisms.
- 2014-2016 Joseph Bautista MD, Renal Fellow, Rhode Island Hospital, Brown University  
Mentor: Dr.Bautista is developing a cost-effective analysis of antimicrobial stewardship programs in out-patient hemodialysis units.
- 2014-2015 Mohamed Alseiari MD, Renal Fellow, Fellow, Rhode Island Hospital, Brown University  
Mentor: Dr. Alseiari is developing a cost-consequence analysis comparing two infection prevention strategies in out-patient dialysis units.
- 2015-2016 Sarah Geffert MD, Infectious Disease Fellow, Rhode Island Hospital, Brown University  
Mentor: Dr Geffert is characterizing risk factors associated with acquisition of multidrug-resistant organisms among patients who have not been exposed to antimicrobials.
- 2016-2017 Jacob Smith MD, Infectious Disease Fellow, Rhode Island Hospital.

2016-2017	Treatment outcomes of endocarditis among intravenous drug users Nicholas Britt PharmD. Assistant Professor of Pharmacy, University of Kansas, Longitudinal analyses of bacteremia and outcomes in the dialysis Population
2016-2018	Jose Ruiz MD, internal medicine resident, Rhode Island Hospital. The role of proton pump inhibitors with dual antiplatelet therapy
2017-2019	Farhan Qadeer MD. Critical Care fellow (previous nephrology fellow) University of Cincinnati Antimicrobial resistance rates of pathogens causing blood stream infections among hospital patients requiring hemodialysis.
2019-2020	Katrina Byrd MD. Infectious Disease fellow, Rhode Island Hospital. Efficacy and safety of sofosbuvir among maintenance hemodialysis patients
2019-2021	Fadi Shehadeh Junior data analyst. Rhode Island Hospital. Efficacy and safety of sofosbuvir among maintenance hemodialysis patients
2019-2020	Mannini Vishwanath MD. Nephrology fellow, Rhode Island Hospital. Outcomes of C.difficile infection among maintenance hemodialysis patients.
2019-2020	Aakriti Pandita MD. Infectious Disease fellow, Rhode Island Hospital. Acquisition of vancomycin-resistant enterococci among patients not exposed to antimicrobials.
2019-2021	Amer Alsamann MD. Hospitalist, Miram Hospital. Antimicrobial resistance among <i>Clostridioides difficile</i> strains
2019-2021	Erick Argueta MD. Internal Medicine Resident, Rhode Island Hospital. Community-acquired <i>Clostridioides difficile</i> infection.
2019-2021	Iliana Escobar. Thesis advisor. New drug development targeting MRSA
2020-2023	Parvathi Radhakrishnan MD, Infectious Disease Fellow, Rhode Island Hospital. Acquisition of vancomycin-resistant enterococci in the absence of antimicrobial exposure
2021-2022	Anuoluwapo Shobayo MD. Infectious Disease Fellow, Rhode Island Hospital. Meta-analysis of <i>Clostridioides difficile</i> prevalence among persons requiring maintenance hemodialysis.
2021-2022	Youseff Elfanagely MD. Internal Medicine Resident, Rhode Island Hospital. Meta-analysis of <i>Clostridioides difficile</i> prevalence among persons requiring maintenance hemodialysis.